Fluidx Closes Series A Funding to Support Trials and Commercialization of the GPX Embolic Device

December 1, 2021—Fluidx Medical Technology announced the closing of the oversubscribed first tranche of its Series A financing round. Fluidx, which is based in Salt Lake City, Utah, is the developer of GPX, an embolic material, as well as other technologies. The funding will be used to support prospective clinical trials of GPX, including the pivotal trial, as well as preparation for market entry.

“GPX has been quite simple to prepare, deliver and control,” commented Andrew Holden, MD, in the company’s press release. “The material is very radiopaque during delivery and has demonstrated excellent distal penetration, particularly important in our tumor embolization cases.” Dr. Holden is Director of Interventional Radiology, Auckland City Hospital in Auckland, New Zealand.

Fluidx advised that the Series A funding was led by a large multinational strategic investor and joined by the company’s existing investor base as well as several new investors.

According to the company, the GPX embolic device is intended to stop blood flow for targeted treatment of hypervascular tumors, vessel malformations, internal bleeds, and other cancer-related uses. The GPX technology is a low viscosity, aqueous-based solution in a syringe that solidifies into a durable embolus upon delivery without polymerization or dimethyl-sulfoxide precipitation. GPX is designed for simple preparation and quick material delivery to occlude blood vessels independent of a patient’s coagulation situation.

On November 2, 2021, Fluidx announced the presentation of data supporting the potential for oncology drug delivery with the GPX embolic device at the Symposium on Clinical Interventional Oncology conference held October 22-24 in Miami Beach, Florida.

In November 2020, the company reported on the investigational use of the GPX device by Dr. Holden to therapeutically devascularize a tumor via a transradial-access procedure. Dr. Holden presented the first patient-use cases with the GPX embolic device at LINC 2021, the Leipzig Interventional Course held January 25-29.